Skip to main content
. 2021 May 12;13(10):2312. doi: 10.3390/cancers13102312

Figure 1.

Figure 1

Flow chart showing the selection steps of the retrospective study and the treatment outcomes of melanoma patients after an initial CR to BRAF/MEKi therapy. We included all patients with an unresectable stage III / IV melanoma receiving BRAF/MEK-inhibitor (i) therapy who showed an initial complete response (CR) (n = 37). Among these 37 patients, 40.5% experienced an ongoing CR, whereas 59.5% showed disease progression during follow-up. 11 patients who showed an ongoing CR continuously received BRAF ± MEKi therapy, whereas 4/15 patients discontinued TT previously, but yet showed an ongoing CR. Notably, most patients with an ongoing CR received initial BRAF ± MEKi therapy for a longer interval than 12 months. By contrast, patients showing a disease progression after initial CR, received BRAF ± MEKi therapy for less than 12 months and most patients experienced disease progression (PD) during BRAF ± MEKi therapy.